Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Launched by ASTRAZENECA · Jun 13, 2024

Keywords

ClinConnect Summary

The MaesTTRo study is looking at patients with transthyretin amyloidosis (ATTR), a condition where abnormal proteins build up in the body, affecting various organs. This research aims to understand how the disease progresses over time and to gather information about the treatments patients are using in the real world. One of the treatments being studied is called eplontersen, which helps reduce the harmful proteins in the body. The study is currently recruiting participants aged 18 and older who have a confirmed diagnosis of ATTR amyloidosis and are willing to share their health experiences.

If you decide to participate, you will be asked to provide consent and participate in tracking your health outcomes through questionnaires. However, you will not be eligible if you're already part of another clinical trial for ATTR amyloidosis or if you have certain other types of amyloidosis. This study is an important step in learning more about ATTR and helping improve treatment options for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient willing and able to provide written informed consent to participate in the study
• • Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
• • Aged ≥18 years at the time of signing the informed consent
• • Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
• Exclusion Criteria:
• • Concurrent participation in any interventional trial for ATTR amyloidosis
• • Involvement in the planning and/or conduct of the current study
• • Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
• • Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers